IBRX vs. SWTX, ACLX, IMCR, APGE, IOVA, DNLI, BEAM, CGON, RXRX, and KYMR
Should you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include SpringWorks Therapeutics (SWTX), Arcellx (ACLX), Immunocore (IMCR), Apogee Therapeutics (APGE), Iovance Biotherapeutics (IOVA), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), CG Oncology (CGON), Recursion Pharmaceuticals (RXRX), and Kymera Therapeutics (KYMR). These companies are all part of the "biological products, except diagnostic" industry.
ImmunityBio (NASDAQ:IBRX) and SpringWorks Therapeutics (NASDAQ:SWTX) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations.
8.6% of ImmunityBio shares are owned by institutional investors. 83.4% of ImmunityBio shares are owned by insiders. Comparatively, 7.4% of SpringWorks Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
SpringWorks Therapeutics has higher revenue and earnings than ImmunityBio. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.
SpringWorks Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -93,761.41%. ImmunityBio's return on equity of 0.00% beat SpringWorks Therapeutics' return on equity.
ImmunityBio has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
SpringWorks Therapeutics received 85 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 67.69% of users gave SpringWorks Therapeutics an outperform vote while only 13.64% of users gave ImmunityBio an outperform vote.
In the previous week, ImmunityBio had 5 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 8 mentions for ImmunityBio and 3 mentions for SpringWorks Therapeutics. SpringWorks Therapeutics' average media sentiment score of 1.08 beat ImmunityBio's score of 0.16 indicating that SpringWorks Therapeutics is being referred to more favorably in the news media.
ImmunityBio presently has a consensus price target of $5.00, indicating a potential downside of 9.42%. SpringWorks Therapeutics has a consensus price target of $68.00, indicating a potential upside of 36.05%. Given SpringWorks Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe SpringWorks Therapeutics is more favorable than ImmunityBio.
Summary
SpringWorks Therapeutics beats ImmunityBio on 10 of the 18 factors compared between the two stocks.
Get ImmunityBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
ImmunityBio Competitors List
Related Companies and Tools